Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners (CRANIO4US)
Primary Purpose
Breast Cancer, Complementary Therapies
Status
Not yet recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Craniosacral therapy
Craniosacral self-help group training
Treatment as usal / wait list
Sponsored by

About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring Craniosacral Therapy, Breast cancer, Randomized Controlled Trial, Self-help strategies, Self-efficacy, Coping
Eligibility Criteria
Inclusion Criteria:
- Breast cancer (stage I-III) survivors after finishing curative chemotherapy and/or radiation
- Impaired breast caner-related quality of life (< 112,8 points on the FACT-B)
- Partner who is willig to participate in the group training
Exclusion Criteria:
- Planned surgery, adjuvant therapy (chemotherapy and/or radtiation), or rehabilitation during the study period
- Pregnancy
- Simultaneous participation in other clinical trials
Sites / Locations
- Center for Integrative Medicine and Planetary Health, University Hospital Essen, University of Duisburg-Essen
- Breast Unit, Evang. Kliniken Essen-Mitte
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Other
Arm Label
Craniosacral therapy
Craniosacral self-help group training
Treatment as usual / wait list control
Arm Description
24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
Waiting period of six months.
Outcomes
Primary Outcome Measures
Breast cancer-related quality of life - total score
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life as a total score of 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Secondary Outcome Measures
Breast cancer-related quality of life - sub scores
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life on 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Breast cancer-related quality of life - total score
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items (4 general subscales and one breast-cancer specific subscale, which will be summarized to a total score) and assesses the specific breast cancer-related quality of life. A higher score indicates a higher cancer-related quality of life.
Breast cancer-related quality of life - sub scores
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life on 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Fatigue
Functional Assessment of Cancer Therapy - Fatigue (FACT-F) Questionnaire: The addoitional F-scale of the FACT consists of 13 self-report items and assesses fatigue related to cancer on 1 scale. A higher score indicates a higher cancer-related fatigue.
Fatigue
Functional Assessment of Cancer Therapy - Fatigue (FACT-F) Questionnaire: The addoitional F-scale of the FACT consists of 13 self-report items and assesses fatigue related to cancer on 1 scale. A higher score indicates a higher cancer-related fatigue.
Endocrine symptoms
Funcitonal Assessment of Cancer - Endocrine Symptom (FACT-ES) Questionnaire: The additonal ES-scale of the FACT consists of 19 self-report items and assesses symptoms related to the endocrine system / antihormonal therapy on 1 scale. A higher score indicates a higher endocrine symptoms.
Endocrine symptoms
Funcitonal Assessment of Cancer - Endocrine Symptom (FACT-ES) Questionnaire: The additonal ES-scale of the FACT consists of 19 self-report items and assesses symptoms related to the endocrine system / antihormonal therapy on 1 scale. A higher score indicates a higher endocrine symptoms.
Sleep disturbance
Patient related outcomes measurement information system - sleep disturbance (PROMIS-SD) Short form: The SD-short form of the PROMIS consists of 8 self-report items and assesses the disturbance of sleep on 1 scale. A higher score indicates higher disturbances of the sleep.
Sleep disturbance
Patient related outcomes measurement information system - sleep disturbance (PROMIS-SD) Short form: The SD-short form of the PROMIS consists of 8 self-report items and assesses the disturbance of sleep on 1 scale. A higher score indicates higher disturbances of the sleep.
Severity of insomnia
Insomnia Severity Index (ISI): The ISI consists of 7 self-report items and assesses the severity of insomnia on 1 scale. A higher score indicates higher severity of insomnia.
Severity of insomnia
Insomnia Severity Index (ISI): The ISI consists of 7 self-report items and assesses the severity of insomnia on 1 scale. A higher score indicates higher severity of insomnia.
State anxiety
Patient related outcomes measurement information system - anxiety/emotional distress (PROMIS-A/ED) Short form: The A/ED-short form of the PROMIS consists of 7 self-report items and assesses state anxiety on one scale. A higher score indicates higher anxiety.
State anxiety
Patient related outcomes measurement information system - anxiety/emotional distress (PROMIS-A/ED) Short form: The A/ED-short form of the PROMIS consists of 7 self-report items and assesses state anxiety on one scale. A higher score indicates higher anxiety.
Fear of recurrence
The Fear of Relapse/Recurrence Scale (FRRS): The FRRS consists of 5 self-report items and assesses the fear of cancer recurrence on one scale. A higher score indicates higher fear of recurrence.
Fear of recurrence
The Fear of Relapse/Recurrence Scale (FRRS): The FRRS consists of 5 self-report items and assesses the fear of cancer recurrence on one scale. A higher score indicates higher fear of recurrence.
Severity of depressive symptoms
Center for epdiemiologic studies depression scale (CES-D): The CES-D consists of 10 self-report items and assesses the severity of depressive symptoms on one scale. A higher score indicates higher severity of depressive symptoms.
Severity of depressive symptoms
Center for epdiemiologic studies depression scale (CES-D): The CES-D consists of 10 self-report items and assesses the severity of depressive symptoms on one scale. A higher score indicates higher severity of depressive symptoms.
Number of patients with adverse events
The number of patients with adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Number of patients with adverse events
The number of patients with adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Total number, type, and grade of adverse events
The total number, type and grade of adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Total number, type, and grade of adverse events
The total number, type and grade of adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Full Information
NCT ID
NCT04319510
First Posted
March 20, 2020
Last Updated
September 4, 2023
Sponsor
Universität Duisburg-Essen
1. Study Identification
Unique Protocol Identification Number
NCT04319510
Brief Title
Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners
Acronym
CRANIO4US
Official Title
Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universität Duisburg-Essen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Craniosacral Therapy (CST) is a non-manipulative, very gentle, manual treatment method that aims to release restrictions of the fasciae and regulate the arousal of the sympathetic nervous system, which is often increased in chronically ill patients. Initial randomized trials support CST's efficacy and effectiveness in reducing symptoms of patients with psychosomatic and chronic pain disorders. To date, there is no trial investigating the effectiveness of CST as a supportive strategy for enhancing cancer-related quality of life in women with breast cancer. In clinical practice, therapists also report alleviating as well as regulating effects of simple CST self-help techniques, offered to patients within a group concept.
Within the recent study, a CST treatment and self-help protocol for women after curative therapy of breast cancer was developed and shall be tested against a waiting list control group. The first group will receive 24 units of CST treatment in a 1:1 setting with a certified craniosacral therapist over 12 weeks. The second group will receive 24 units of group training in CST self-help techniques offered by a certified craniosacral therapist over 12 weeks. They will be reassessed after 12 and 26 weeks (6 months) after randomization. The third group will wait for 26 weeks and will receive no specific study intervention. After 26 weeks patients of the third group were offered to take part in two individual CST interventions and the CST self-help training. For all groups, treatment as usual is allowed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Complementary Therapies
Keywords
Craniosacral Therapy, Breast cancer, Randomized Controlled Trial, Self-help strategies, Self-efficacy, Coping
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Masking Description
The investigator who will perform the group assignment will have no contact to the study participants. The outcome assessors will be blinded to group allocation. The statistician who will perform the analyses will kept blind to the group intervention by renaming groups with numbers.
Allocation
Randomized
Enrollment
102 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Craniosacral therapy
Arm Type
Experimental
Arm Description
24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
Arm Title
Craniosacral self-help group training
Arm Type
Experimental
Arm Description
24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
Arm Title
Treatment as usual / wait list control
Arm Type
Other
Arm Description
Waiting period of six months.
Intervention Type
Procedure
Intervention Name(s)
Craniosacral therapy
Intervention Description
The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
Intervention Type
Procedure
Intervention Name(s)
Craniosacral self-help group training
Intervention Description
The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
Intervention Type
Procedure
Intervention Name(s)
Treatment as usal / wait list
Intervention Description
The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered 2 treatments (4TUS) of 1:1 CST and the participation in the group training.
Primary Outcome Measure Information:
Title
Breast cancer-related quality of life - total score
Description
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life as a total score of 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Time Frame
week 12
Secondary Outcome Measure Information:
Title
Breast cancer-related quality of life - sub scores
Description
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life on 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Time Frame
week 12
Title
Breast cancer-related quality of life - total score
Description
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items (4 general subscales and one breast-cancer specific subscale, which will be summarized to a total score) and assesses the specific breast cancer-related quality of life. A higher score indicates a higher cancer-related quality of life.
Time Frame
week 26
Title
Breast cancer-related quality of life - sub scores
Description
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire: The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life on 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.
Time Frame
week 26
Title
Fatigue
Description
Functional Assessment of Cancer Therapy - Fatigue (FACT-F) Questionnaire: The addoitional F-scale of the FACT consists of 13 self-report items and assesses fatigue related to cancer on 1 scale. A higher score indicates a higher cancer-related fatigue.
Time Frame
week 12
Title
Fatigue
Description
Functional Assessment of Cancer Therapy - Fatigue (FACT-F) Questionnaire: The addoitional F-scale of the FACT consists of 13 self-report items and assesses fatigue related to cancer on 1 scale. A higher score indicates a higher cancer-related fatigue.
Time Frame
week 26
Title
Endocrine symptoms
Description
Funcitonal Assessment of Cancer - Endocrine Symptom (FACT-ES) Questionnaire: The additonal ES-scale of the FACT consists of 19 self-report items and assesses symptoms related to the endocrine system / antihormonal therapy on 1 scale. A higher score indicates a higher endocrine symptoms.
Time Frame
week 12
Title
Endocrine symptoms
Description
Funcitonal Assessment of Cancer - Endocrine Symptom (FACT-ES) Questionnaire: The additonal ES-scale of the FACT consists of 19 self-report items and assesses symptoms related to the endocrine system / antihormonal therapy on 1 scale. A higher score indicates a higher endocrine symptoms.
Time Frame
week 26
Title
Sleep disturbance
Description
Patient related outcomes measurement information system - sleep disturbance (PROMIS-SD) Short form: The SD-short form of the PROMIS consists of 8 self-report items and assesses the disturbance of sleep on 1 scale. A higher score indicates higher disturbances of the sleep.
Time Frame
week 12
Title
Sleep disturbance
Description
Patient related outcomes measurement information system - sleep disturbance (PROMIS-SD) Short form: The SD-short form of the PROMIS consists of 8 self-report items and assesses the disturbance of sleep on 1 scale. A higher score indicates higher disturbances of the sleep.
Time Frame
week 26
Title
Severity of insomnia
Description
Insomnia Severity Index (ISI): The ISI consists of 7 self-report items and assesses the severity of insomnia on 1 scale. A higher score indicates higher severity of insomnia.
Time Frame
week 12
Title
Severity of insomnia
Description
Insomnia Severity Index (ISI): The ISI consists of 7 self-report items and assesses the severity of insomnia on 1 scale. A higher score indicates higher severity of insomnia.
Time Frame
week 26
Title
State anxiety
Description
Patient related outcomes measurement information system - anxiety/emotional distress (PROMIS-A/ED) Short form: The A/ED-short form of the PROMIS consists of 7 self-report items and assesses state anxiety on one scale. A higher score indicates higher anxiety.
Time Frame
week 12
Title
State anxiety
Description
Patient related outcomes measurement information system - anxiety/emotional distress (PROMIS-A/ED) Short form: The A/ED-short form of the PROMIS consists of 7 self-report items and assesses state anxiety on one scale. A higher score indicates higher anxiety.
Time Frame
week 26
Title
Fear of recurrence
Description
The Fear of Relapse/Recurrence Scale (FRRS): The FRRS consists of 5 self-report items and assesses the fear of cancer recurrence on one scale. A higher score indicates higher fear of recurrence.
Time Frame
week 12
Title
Fear of recurrence
Description
The Fear of Relapse/Recurrence Scale (FRRS): The FRRS consists of 5 self-report items and assesses the fear of cancer recurrence on one scale. A higher score indicates higher fear of recurrence.
Time Frame
week 26
Title
Severity of depressive symptoms
Description
Center for epdiemiologic studies depression scale (CES-D): The CES-D consists of 10 self-report items and assesses the severity of depressive symptoms on one scale. A higher score indicates higher severity of depressive symptoms.
Time Frame
week 12
Title
Severity of depressive symptoms
Description
Center for epdiemiologic studies depression scale (CES-D): The CES-D consists of 10 self-report items and assesses the severity of depressive symptoms on one scale. A higher score indicates higher severity of depressive symptoms.
Time Frame
week 26
Title
Number of patients with adverse events
Description
The number of patients with adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
week 12
Title
Number of patients with adverse events
Description
The number of patients with adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
week 26
Title
Total number, type, and grade of adverse events
Description
The total number, type and grade of adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
week 12
Title
Total number, type, and grade of adverse events
Description
The total number, type and grade of adverse events and serious adverse events will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
week 26
Other Pre-specified Outcome Measures:
Title
Expectations about treatment efficacy
Description
Treatment Credibility Scale (TCS): The TCS consists of 4 self-report items, which are answered on a Numeric Rating Scale (NRS). One item asks about the expectations of efficacy of the study treatments and 3 items about treatment credibility (see below). A higher score indicates higher treatment expectations.
Time Frame
week 0
Title
Expectations about self-efficacy
Description
Numeric Rating Scale (NRS): Expectations about the self-efficacy of performing the learned CST techniques at home were assessed using a self-report NRS. A higher score indicates higher expectations of self-efficacy.
Time Frame
week 0
Title
Treatment Credibility
Description
Treatment Credibility Scale (TCS): The TCS consists of 4 self-report items, which are answered on a Numeric Rating Scale (NRS). One item asks about the expectations of efficacy of the study treatments (se above) and 3 items about treatment credibility. A higher score indicates higher treatment credibility.
Time Frame
week 12
Title
Relation between therapist and patient
Description
Helping Alliance Questionnaire (HAQ): The HAQ consists of 11self-report items and assesses the therapeutic relation on two subscales: quality of the therapeutic relation and satisfaction with the treatment. A higher score indicates a higher quality of the therapeutic relation / a higher satisfaction with the treatment.
Time Frame
week 12
Title
Actually received social support
Description
Berlin Social Support Scales - Actually Received Support (BSSS-ARS) subscale: The BSSS-ARS consists of 15 self-report items and assesses the actually received social support on 4 subscales: emotional support, instrumental support, informational support, and satisfaction with support. A higher score indicates higher received social support.
Time Frame
week 12
Title
Actually received social support
Description
Berlin Social Support Scales - Actually Received Support (BSSS-ARS) subscale: The BSSS-ARS consists of 15 self-report items and assesses the actually received social support on 4 subscales: emotional support, instrumental support, informational support, and satisfaction with support. A higher score indicates higher received social support.
Time Frame
week 26
Title
Body Awareness
Description
Body Responsiveness Questionnaire (BRQ): The BRQ consists of 7 self-report items and assesses body awareness on 3 subscales: Importance of Interoceptive Awareness, Perceived Connection, and Suppression of Bodily Sensations. A higher score indicates higher body awareness on the subscales Importance of Interoceptive Awareness and Perceived Connection, while a higher score indicates lower body awareness on the subscale Suppression of Bodily Sensations.
Time Frame
week 12
Title
Body Awareness
Description
Body Responsiveness Questionnaire (BRQ): The BRQ consists of 7 self-report items and assesses body awareness on 3 subscales: Importance of Interoceptive Awareness, Perceived Connection, and Suppression of Bodily Sensations. A higher score indicates higher body awareness on the subscales Importance of Interoceptive Awareness and Perceived Connection, while a higher score indicates lower body awareness on the subscale Suppression of Bodily Sensations.
Time Frame
week 26
Title
Interview
Description
Semi-structured interview: A pre-developed semi-structured interview guide asks about the personal experiences with the effects and safety of craniosacral therapy/self-help techniques.
Time Frame
week 12
Title
Craniosacral-specific quality of life
Description
Warwick Holistic Health Questionnaire (WHHQ): The WHHQ consists of 25 self-report items and assesses craniosacral-specific quality of life on one scale. A higher score indicates higher craniosacral-specific quality of life. The German version of the WHHQ shall be validated within this trial.
Time Frame
week 12
Title
Craniosacral-specific quality of life
Description
Warwick Holistic Health Questionnaire (WHHQ): The WHHQ consists of 25 self-report items and assesses craniosacral-specific quality of life on one scale. A higher score indicates higher craniosacral-specific quality of life. The German version of the WHHQ shall be validated within this trial.
Time Frame
week 26
Title
Duration of homework
Description
The duration of performing the CST techniques at home (for group 2) will be assessed using a diary.
Time Frame
week 1-12
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Breast cancer (stage I-III) survivors after finishing curative chemotherapy and/or radiation
Impaired breast caner-related quality of life (< 112,8 points on the FACT-B)
Exclusion Criteria:
Planned surgery, adjuvant therapy (chemotherapy and/or radtiation), or rehabilitation during the study period
Pregnancy
Simultaneous participation in other clinical trials
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Heidemarie Haller, PhD
Phone
+4920172377384
Email
heidemarie.haller@uk-essen.de
First Name & Middle Initial & Last Name or Official Title & Degree
Holger Cramer, PhD
Email
holger.cramer@med.uni-tuebingen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gustav Dobos, Prof. MD
Organizational Affiliation
Center for Integrative Medicine and Planetary Health, University Hospital Essen, University of Duisburg-Essen
Official's Role
Study Director
Facility Information:
Facility Name
Center for Integrative Medicine and Planetary Health, University Hospital Essen, University of Duisburg-Essen
City
Essen
ZIP/Postal Code
45130
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heidemarie Haller, PhD
Phone
+4920172377384
Email
heidemarie.haller@uk-essen.de
Facility Name
Breast Unit, Evang. Kliniken Essen-Mitte
City
Essen
ZIP/Postal Code
45276
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sherko Kümmel, Prof. MD
Email
d.schindowski@kem-med.com
First Name & Middle Initial & Last Name & Degree
Petra Voiss, MD
Email
p.voiss@kem-med.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners
We'll reach out to this number within 24 hrs